Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, and Morphology Department, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.
Nephrol Dial Transplant. 2012 Jul;27(7):2720-33. doi: 10.1093/ndt/gfr671. Epub 2012 Feb 1.
Angiotensin receptor 1 blockers (ARB) are standard nephroprotective drugs in chronic kidney disease. There is less evidence for a nephroprotective effect of HMG-CoA reductase inhibitors (statins) and much less is known about potential benefits of combination therapy. We evaluated the therapeutic potential of a statin alone or in combination with an ARB in experimental chronic kidney disease.
Subtotally nephrectomized (5/6 Nx) rats were treated early with vehicle, losartan, cerivastatin or losartan/cerivastatin. Expression of messenger RNA (mRNA) was assessed by real-time reverse transcription-polymerase chain reaction. Tissue proteins were localized by immunohistochemistry. Nuclear factor-κB (NF-κB) activation was measured in whole kidneys.
In contrast to the sham group, at 6 weeks, vehicle-treated 5/6 Nx rats displayed renal lesions, albuminuria and increased blood pressure, serum creatinine and total kidney NF-κB p65 DNA-binding activity and preproendothelin-1, fibronectin and type I and III collagen mRNA. NF-κB activation correlated with albuminuria and histological renal injury. Losartan or combination therapy preserved renal function, abrogated albuminuria and improved glomerular and interstitial histology. Cerivastatin alone preserved renal function and improved interstitial injury but did not influence albuminuria, glomerular histology or NF-κB activation. Losartan/cerivastatin normalized kidney NF-κB activation and extracellular matrix mRNA expression pattern. The effect of losartan alone on these parameters was less intense. All treatments decreased preproendothelin-1 mRNA and preserved interstitial capillaries.
In a chronic kidney disease model, early treatment with either an ARB or a statin preserved renal function although the mechanisms differed. Combination therapy with an ARB and a statin did not confer clear-cut advantages on biochemical and histological parameters over ARB alone, although it further improved the kidney NF-κB and gene expression profile.
血管紧张素受体 1 阻滞剂(ARB)是慢性肾脏病的标准肾脏保护药物。对于羟甲基戊二酰辅酶 A 还原酶抑制剂(他汀类药物)的肾脏保护作用的证据较少,而对于联合治疗的潜在益处则知之甚少。我们评估了他汀类药物单独或与 ARB 联合治疗实验性慢性肾脏病的治疗潜力。
部分肾切除术(5/6 Nx)大鼠早期给予载体、氯沙坦、西立伐他汀或氯沙坦/西立伐他汀治疗。通过实时逆转录-聚合酶链反应评估信使 RNA(mRNA)的表达。免疫组织化学定位组织蛋白。测量全肾核因子-κB(NF-κB)的激活。
与假手术组相比,6 周时,载体治疗的 5/6 Nx 大鼠显示出肾脏病变、白蛋白尿和血压升高、血清肌酐和全肾 NF-κB p65 DNA 结合活性以及前内皮素-1、纤维连接蛋白和 I 型和 III 型胶原 mRNA 增加。NF-κB 激活与白蛋白尿和组织学肾损伤相关。氯沙坦或联合治疗可维持肾功能,消除白蛋白尿,改善肾小球和间质组织学。西立伐他汀单独治疗可维持肾功能并改善间质损伤,但不影响白蛋白尿、肾小球组织学或 NF-κB 激活。氯沙坦/西立伐他汀可使肾脏 NF-κB 激活和细胞外基质 mRNA 表达模式正常化。氯沙坦单独对这些参数的作用较弱。所有治疗均降低前内皮素-1 mRNA 并保留间质毛细血管。
在慢性肾脏病模型中,ARB 或他汀类药物的早期治疗可维持肾功能,尽管作用机制不同。ARB 联合他汀类药物在生化和组织学参数方面并未优于单独使用 ARB,尽管它进一步改善了肾脏 NF-κB 和基因表达谱。